Nuclidium

Switzerland
Breíl, Grisons, Switzerland, 4051

Company profile

Nuclidium company profile

NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics.

Business identity

Contact email
[email protected]
Phone number
+41 78 326 6666
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0-$1M
Founded
2018-01-01, Year

Headquarters

Postal code
4051
Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
3
Total equity funding
$102M
Last funding
Series B / $99.2M / 2025-07-10
Last equity funding
Series B / $99.2M
Investors
12
Lead investors
5
Founders
2
Articles
40

Founders and investors

Founders

Gustav SchulthessLeila Jaafar-Thiel

Lead investors

Angelini VenturesEuropean Innovation CouncilKurma PartnersNeva SGRWellington Partners

Investors

European Innovation CouncilHighlight CapitalKurma PartnersNRW.BANKWellington Partners